EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody–drug conjugates

Aiko Yamaguchi, Junping Hong, Leike Li, Kiyotaka Kobayashi, Chisato M Yamazaki, Summer Y Y Ha iD, Yasuaki Anami, Wei Xiong, Junquan Liu iD, Zhiqiang An iD, Ningyan Zhang, Kyoji Tsuchikama iD

Antibody Therapeutics · 01.04.2026 · 9 (2) · 127-138

DOI: 10.1093/abt/tbag011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 13.03.2026. Verfasst von Aiko Yamaguchi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science C…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute of the National Institutes of Health, Department of Defense Breast Cancer Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trophoblast cell surface antigen 2 (TROP2) is frequently overexpressed in epithelial tumors and is associated with poor prognosis, making it an attractive therapeutic target. Antibody–drug conjugates (ADCs) directed against TROP2 show clinical benefit, but expression in normal tissues such as skin raises concerns about on-target, off-tumor toxicity. Strategies that improve antitumor efficacy without increasing toxicity are needed.

Methods

Using an in-house phage library, we identified and characterized a novel fully human monoclonal antibody recognizing a unique conformational epitope of TROP2 with reduced binding affinity. This antibody was engineered into homogeneous ADCs carrying auristatin and/or duocarmycin payloads. Comparative studies with a surrogate of sacituzumab govitecan were performed in TROP2-expressing tumor models.

Results

The novel ADCs demonstrated remarkable antitumor activity in mouse xenograft and syngeneic tumor models. Despite lower binding affinity, the novel antibody exhibited potent efficacy, suggesting that epitope selection and affinity tuning can be leveraged to enhance therapeutic outcomes.

Conclusions

Novel anti-TROP2 ADCs offer a promising approach for assuring efficacy while potentially mitigating toxicity. Optimization of antibody binding properties may enable the development of safer and more effective TROP2-targeted therapeutics.

Schlagwörter

Stichwörter der Autor:innen

TROP2antibody–drug conjugatesbreast cancerdrug deliverydual payload

Autor:innen und Institutionen

  • Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), 7255 Helix Park Ave., Houston, TX…
  • Department of Radiopharmaceuticals for Advanced Diagnostic Imaging and Therapy, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, 1881 East Rd., Houston, TX 77054, United States.
  • Center for Retrovirus Research, The Ohio State University, 1900 Coffey Rd., Columbus, OH 43210, United States.
  • Global Biologics, Takeda Pharmaceuticals, 35 Landsdowne St., Cambridge, MA 02139, United States.
  • CrossBridge Bio, Inc., 7255 Helix Park Ave., Houston, TX 77030, United States.

ORCID-Profile: Summer Y Y Ha, Junquan Liu, Zhiqiang An, Kyoji Tsuchikama

Förderung

  • NCI NIH HHS
  • National Cancer Institute of the National Institutes of Health
  • Department of Defense Breast Cancer Research Program
  • Cancer Prevention and Research Institute of Texas
  • Welch Foundation
  • Japan Society for the Promotion of Science
  • CPRIT Cancer Therapeutics Training Program

Zitieren

APA

Yamaguchi, A., Hong, J., Li, L., Kobayashi, K., Yamazaki, C. M., Ha, S. Y. Y., Anami, Y., Xiong, W., Liu, J., An, Z., Zhang, N., & Tsuchikama, K. (2026). Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody–drug conjugates. Antibody Therapeutics, 9(2), 127-138. https://doi.org/10.1093/abt/tbag011

Vancouver

Yamaguchi A, Hong J, Li L, Kobayashi K, Yamazaki CM, Ha SYY, et al. Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody–drug conjugates. Antibody Therapeutics. 2026;9(2):127-138. doi:10.1093/abt/tbag011

BibTeX
@article{Yamaguchi2026,
  author = {Yamaguchi, Aiko and Hong, Junping and Li, Leike and Kobayashi, Kiyotaka and Yamazaki, Chisato M and Ha, Summer Y Y and Anami, Yasuaki and Xiong, Wei and Liu, Junquan and An, Zhiqiang and Zhang, Ningyan and Tsuchikama, Kyoji},
  title = {Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody–drug conjugates},
  journal = {Antibody Therapeutics},
  year = {2026},
  volume = {9},
  number = {2},
  pages = {127--138},
  doi = {10.1093/abt/tbag011}
}
Kostenlos starten →